Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
12:05pm, Wednesday, 24'th Dec 2025
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
Here's Why Shares in Agios Pharmaceuticals Popped Today
12:03pm, Wednesday, 24'th Dec 2025
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappoint
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
08:22am, Wednesday, 24'th Dec 2025
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
07:45pm, Tuesday, 23'rd Dec 2025
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemi
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
11:26am, Tuesday, 09'th Dec 2025
AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
07:00am, Monday, 08'th Dec 2025
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO
04:34am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 8.5% during the undefined quarter, according to the company in its most recent disclosure with the S
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
01:36pm, Thursday, 20'th Nov 2025
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript
02:33pm, Wednesday, 19'th Nov 2025
Agios Pharmaceuticals, Inc. ( AGIO ) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST Company Participants Morgan Sanford Brian Go
Why Shares in Agios Pharmaceuticals Got Crushed Today
01:33pm, Wednesday, 19'th Nov 2025
Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026.
Why Is Agios Pharmaceuticals Stock Sinking Today?
12:30pm, Wednesday, 19'th Nov 2025
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.
Agios Pharma reports mixed results in late-stage study for sickle cell disease drug
08:24am, Wednesday, 19'th Nov 2025
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
07:00am, Wednesday, 19'th Nov 2025
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did n
Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $57.25
02:54am, Tuesday, 04'th Nov 2025
Shares of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBe
Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones
01:47am, Tuesday, 04'th Nov 2025
Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd'
